A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Trial Profile

A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs LIK 066 (Primary)
  • Indications Non-alcoholic steatohepatitis; Obesity
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 10 Aug 2019 to 13 Apr 2019.
    • 24 Jul 2017 Planned primary completion date changed from 10 Aug 2019 to 13 Apr 2019.
    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top